2020 CSCO Conference opens, wonderful non-stop!

The theme of the 2020 CSCO Annual Meeting is "Precise diagnosis and treatment, win-win cooperation".
conference is a star-gathered gathering of top experts in the field of oncology.
invited Fellow Wu Mengchao of Shanghai Oriental Hepatocholine Surgery Hospital, Fellow Sun Yan of the Oncology Hospital of the Chinese Academy of Medical Sciences, Professor Liao Meilin of Shanghai Chest Hospital, and Professor Guan Zhongzhen of Sun Yat-sen University Cancer Prevention and Control Center.
Chinese Academy of Medical Sciences Oncology Hospital, CSCO President He Jie academician, Tongji University affiliated Oriental Hospital Professor Li Jin co-chaired the General Assembly, CSCO Vice President, PLA General Hospital Fifth Medical Center Professor Jiang Zefei, CSCO Associate Director, Professor Wang Jie of the Chinese Academy of Medical Sciences Oncology Hospital as Secretary-General of the General Assembly.
Professor Jiang Zefei delivered a message to Professor Jiang Zefei to give a welcoming speech to the General Assembly and introduced the guests, Sun Yan, Professor Liao Meilin, Professor Guan Zhongzhen through video, from the cloud to bring sincere blessings.
, CSCO Chairman Academician Hertzer addressed the General Assembly.
his speech, the academician noted that 2020 will be an extraordinary year, isolating the epidemic, but not academic exchanges.
CSCO shoulder the heavy responsibility of cancer prevention and treatment, I hope that this event, through the sincere cooperation of colleagues from all walks of life to promote the development of CSCO, to achieve accurate diagnosis and treatment of tumors.
, a member of the Beijing Concord Medical College of the Chinese Academy of Medical Sciences, also sent blessings via remote connection! Academician Wang Chen delivered a speech by remote connection from the Beijing Concord Medical College of the Chinese Academy of Medical Sciences.
Wang Chen said that the problem of tumor prevention and control is becoming more and more prominent, really do a good job of tumor prevention and control, need to work hard in the early stages of tumor development, which is the most important and prominent problem.
, for example, smoking is the most preventable risk factor for disease and is associated with tumors, respiratory diseases, cardiovascular diseases, and many chronic diseases.
second is to pay attention to the early diagnosis and treatment of tumors.
Taking lung cancer as an example, 80% of patients diagnosed with lung cancer are in advanced stages, the overall survival rate of 5 years is 15%-17%, the five-year survival rate of early lung cancer is more than 70%, and the 10-year survival rate of IA lung cancer is more than 92%.
, Professor Wang Chen emphasized the concept of "group medicine", which tends to benefit the whole group the most in the face of limited medical resources.
MDT also comes from "group medicine", and the rational application of "group medicine" will play an important role in the overall prevention and treatment of tumors.
Award Ceremony - Annual Achievement Award Professor Ma Jun of Harbin Institute of Hematology Oncology announced the winner of the "Achievement of the Year Award", Professor Qin Shuxuan of the Eastern War Zone General Hospital received this award, and Professor Yu Jia of Zhongshan Hospital, affiliated with Fudan University, presented the award to Professor Qin Shuxuan.
his acceptance speech, Professor Qin Shuxuan expressed his vision of not forgetting his first thoughts and moving forward.
Ma Jun of Harbin Hematological Oncology Research Institute was awarded the "Achievement of the Year Award" by Professor Qin Shuxuan of the Eastern War Zone General Hospital, and the guest of honor was a fellow of Sun Yat-sen Hospital affiliated with Fudan University.
In his acceptance speech, Professor Qin Shuxuan expressed his gratitude to Wu Mengchao, Sun Yan, Guan Zhongzhen and Liao Meilin, the leaders of the State Drug Administration, CSCO colleagues, sincere cooperation experts, unit colleagues! and said that will not forget the first heart, move forward.
Excellent Papers First Prize RATINOALE 307 Research, Professor Wang Jie and others (Oncology Hospital of the Chinese Academy of Medical Sciences) Second Prize HLX04 related 3 studies, Professor Li Jin and others (Shanghai Tongji University Affiliated Oriental Hospital) POLARIS-03 Research, Guo Jun, Professor Sheng Xinan and other (Beijing University Cancer Hospital) 3rd Prize Professor Shen Lin, etc. won the third prize.
include: phase 2 clinical studies of KN035 treatment of solid tumors, IMbrave 150 study of Subgroup Analysis in China, RC48-ADC treatment of HER2-positive stomach cancer, albumin yew alcohol co-gio or Gisithamin joint Clinical trials for the treatment of local or metastatic pancreatic cancer in Tygio, DLBCL for the treatment of Ibdenib-RCHOP, HLX02 biosyntherapy studies, PD-L1 antibody ZKAB001 for the treatment of relapsed metastatic cervical cancer, etc.
Professor Zhan Qimin of Peking University shared a special report on "Combating the Outbreak of New Crown Pneumonia and the Development of Healthy China", introducing "New Crown Epidemic and Healthy China's Development" from the new trends and challenges of global health after the new crown epidemic, the prominent position of medicine and health in the national strategic system and the contribution of medical development to promoting social governance under the new situation.
Zhan Qimin pointed out that the path of medical development lies in the concept of "medicine plus X", which will promote cross-type medical innovation and compound talent training.
Through this outbreak, consensus has been reached that medical personnel are the country's most valuable resources, is to guard our life safety and health guards, should form the whole society respect for medical care, advocate the medical and health industry, build a healthy China's good atmosphere.
Professor Qin Shuxuan of the Eastern War Zone General Hospital expounded the Chinese contribution to the progress of liver cancer drug treatment, and Professor Qin introduced the outstanding contribution of Chinese researchers in the field of liver cancer from the four aspects of China's liver cancer overview, liver cancer research conducted in China, the important contribution of Chinese scholars, and the development of Chinese scholars to the world.
Professor Qin said that there is a huge heterogeneity of liver cancer in East and West, Soraphini is currently one of the most commonly used drugs in liver cancer treatment, its research in Europe and Asia have achieved positive results, but from the data, the survival data of East and West are obviously different, we can see the heterogeneity of liver cancer in East and West.
follow-up, CheckMate459, failed, mainly because it confused East and West liver cancer.
KEYNOTE-240 also failed due to a double-end selection problem, did not reach the preset double-end OS and PFS, and finally "bamboo basket water empty."
based on the lessons of failure, the subsequent KEYNOTE-394 study in the Asia-Pacific region circumvented the main flaws in the KEYNOTE-240 design and expected the results to be announced.
REFLECT research is based on previous research success and failure experience, cleverly designed the research program, the current lunphatinist has been successfully listed, for the current lenphatinistini and immunotherapy a number of research to lay the foundation.
happy two dozen one "IMbrave150 research" design is very good, the Chinese team contributed outstandingly, the research reached expectations, the United States has been listed, China will also be listed in the near future.
Under the leadership and exploration of Sun Yan and Professor Qin Shuxuan, arsenicate injections were introduced in China in 2004 to treat advanced liver cancer, ushering in the era of chemotherapy for liver cancer in China and even around the world.
subsequent EACH study represented the first time that Chinese drug research had been on the ASCO stage.
addition, the use of ear particles for postoperative ancillary therapy has been successful, the results of which were published in the journal Gut.
is at the forefront of the world: China's Karelli Pearl Single Resistance has led a new chapter in the treatment of the liver cancer system, and in March this year, Karelli Pearl Single Resistance was approved for listing in China, becoming the only immuno-checkpoint inhibitor approved for liver cancer treatment in China.
year's ASCO Conference, two studies of the treatment of liver cancer by Donaphini and Apatinistini were included in asCO's oral report.
Chinese scholars have grown from participating to being "tide children" and are at the forefront of clinical research on liver cancer drugs around the world.
Professor Qin Shuxuan combed through the progress of drug therapy for primary liver cancer, from chemotherapy to targeted treatment to today's immunotherapy, the treatment of liver cancer has made breakthrough progress, it is gratifying that Chinese scholars, Chinese clinical research in which the contribution is very important.
Qin made special mention of the second-line and above treatment of hepatocellular carcinoma phase II clinical research, in the group of people with late illness, the condition is more serious premise, Karelli pearl single resistance has achieved excellent results.
The study was presented orally at the 2015 ESMO Conference and was published in The Lancet Oncology this year, which is why Karelli Pearl Monoantigen was approved by NMPA on March 18 this year for second-line treatment for advanced liver cancer, becoming the only immunosupgerant approved for liver cancer adaptation in China.
For the adverse reaction RCCEP (reactive skin capillary growth disorder), Professor Qin mentioned that although the occurrence of RCCEP is high, but mostly one or two and more occur in the skin;
this research, Professor Qin Shuxuan was awarded the 2020 CSCO Achievement of the Year Award.
Professor Wang Jie of the Oncology Hospital of the Chinese Academy of Medical Sciences interpreted the RATIONALE 307 study: a Phase III study of patients with advanced squamous non-small cell lung cancer treated with pure chemotherapy first-line chemotherapy, which was first published at this year's ASCO Conference and the latest results were presented at this year's ESMO Conference.
THERATIONALE 307 study is the second Phase III clinical study in which immunological combined therapy achieved better results in lung squamous cancer, following the KEYNOTE-407 study.
compared to pure chemotherapy, the combination of reilly bead monoantigen-resistant yew alcohol/carpentin (HR=0.524, P=0.0001) or albumin yew alcohol/carpentin (HR=0.478, P.0001) can significantly improve progress-free survival.
research supports a new option for the first-line treatment of advanced squamous non-small cell lung cancer with relligoonotic combination chemotherapy.
Professor Li Jin of The Oriental Hospital affiliated with Tongji University in Shanghai detailed the Phase III clinical study of HLX04, which compared the efficacy and safety of HLX04 or Beval pearl monoantigen-based chemotherapy (XELOX or mFOLFOX6) for metastatic colorectal cancer.
results show that HLX04 is equivalent to the effect of beval bead monoantin.
Guo Jun, Professor Guo Jun of Peking University Oncology Hospital, introduced the POLARIS-03 study: A phase II clinical study of Terripri monoantigen for second-line treatment of advanced urethroid skin cancer after standard treatment failure.
POLARIS-03 study was the first key clinical study conducted in the non-selective population of advanced urinary tract cancer that failed standard treatment in China, and the results showed that the objective effectiveness rate of the overall population was 25.8%, the 12-month disease control rate was 68.9%, the medium total survival was 14.4 months, the effective rate of the PD-L1 positive subgroup was 41.7% and the effective rate of the PD-L1 negative subgroup was 16.7%.
safety is consistent with other similar drugs.
in the field of lung cancer in recent years, immunotherapy has developed rapidly in the field of lung cancer.
key layout of cornerstone pharmaceutical industry in immunotherapy, CS1001 combined chemotherapy for scaly and non-scaly NSCLC clinical trials have been successful, detailed results will be announced soon.
same time, a clinical study using CS1001 to maintain treatment after NSCLC chemotherapy is under way.
CS1001 is expected to be a new weapon in immunotherapy.
, Professor Fan Yun in the "Biomarker Detection Guide NSCLC Precision Therapy" report, the current late NSCLC treatment has entered the era of precision medicine, biomarker detection is the cornerstone of precision therapy.
2020 NCCN guidelines strongly recommend testing for rare drive mutations that already have access to drugs, such as RET gene fusion, NTRK gene fusion, MET gene mutations, and ERBB2 mutations.
the biomarkers currently approved for NSCLC immunotherapy are mainly PD-L1 and TMB, but it is still not possible to accurately determine the effectiveness of patients in immunotherapy, and the study of new biomarkers is still under exploration.
Miya Youling of the Lu uranium team at Huaxi Hospital, Sichuan University, made a report on "New Advances in NSCLC Immunotherapy Combined Chemotherapy", noting that immunotherapy has synergistic effects and has become the standard treatment for gene-negative NSCLC first-line treatment.
CS1001 is an all-human full-length anti-PD-L1 monoclonal antibody developed by Keystone Pharmaceuticals, CS1001-302 is CS1001 combined chemotherapy as a first-line treatment in phase IV scales and non-scales In randomized, double-blind, and Phase III clinical trials in two histological subtypes of NSCLC, preliminary results showed good efficacy and safety, with CS1001 combined chemotherapy mPFS for 7.8 months and placebo combined chemotherapy mPFS for 4.9 months.
Chang Jianhua, who shared "A New Breakthrough in Targeting Treatment of Rare Gene Mutations in NSCLC", points out that rare drive gene mutations in lung adenocarcinoma are constantly being detected and drugs are progressing rapidly, with a breakthrough in RET-specific inhibitors.
ARROW 1/2 clinical studies have shown that Pralsetinib (BLU-667) 400mg QD treatment RET fusion positive NSCLC is significantly effective and safely controlled;
Pralsetinib has strong intracranial activity, and current data show that the ORR in patients with intracranial metastasis is 56%.
Huang Cheng commented that at present, the two rare targets of clinical concern are the MET and RET genes.
results of the study that re-fusion-positive NSCLC received Pralsetinib targeted therapy were excellent.
with the progress and popularity of testing methods, the detection rate of reT fusion positive NSCLC patients in China is expected to further improve, and It is expected that Pralsetinib will bring greater survival benefits to Chinese patients.
annual meeting of the special Wuhan anti-epidemic special session, the Council led Professor Qin Shuxuan, Professor Li Jin, Yu Jinming academician, Professor Jiang Zefei co-chaired the General Assembly, to discuss discipline construction and patient management experience under the epidemic, anti-epidemic front-line oncologists to share in the outbreak "one-handed anti-epidemic, one-handed anti-cancer" personal feelings.
2020 innovative drug clinical research field is more abundant, including "co-building technical standards, accelerate the development and market of new anti-tumor drugs."